Jasleen Randhawa

Jasleen Randhawa

Hematology | Oncology | Internal Medicine

480 E Division St
Fond Du Lac, WI 54935

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study.

Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study.

Journal: The Lancet. Haematology

Published: January 26, 2023

Use of ifosfamide, carboplatin and etoposide in combination with brentuximab vedotin or romidepsin based on CD30 positivity in relapsed/refractory peripheral T-cell lymphoma.

Use of ifosfamide, carboplatin and etoposide in combination with brentuximab vedotin or romidepsin based on CD30 positivity in relapsed/refractory peripheral T-cell lymphoma.

Journal: Cancer reports (Hoboken, N.J.)

Published: April 16, 2021

Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant.

Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant.

Journal: Blood

Published: October 07, 2020

The development of T-cell malignancies in patients with pre-existing myeloproliferative neoplasms: a report of three cases.

The development of T-cell malignancies in patients with pre-existing myeloproliferative neoplasms: a report of three cases.

Journal: Ecancermedicalscience

Published: September 12, 2019

Primary CNS Lymphoma Arising from the 4th Ventricle: A Case Report and Review of the Literature.

Primary CNS Lymphoma Arising from the 4th Ventricle: A Case Report and Review of the Literature.

Journal: Case reports in oncological medicine

Published: December 11, 2018

A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia.

A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia.

Journal: Acta haematologica

Published: May 09, 2018

Final outcomes of escalated melphalan 280 mg/m2 with amifostine cytoprotection followed autologous hematopoietic stem cell transplantation for multiple myeloma: high CR and VGPR rates do not translate into improved survival.

Final outcomes of escalated melphalan 280 mg/m2 with amifostine cytoprotection followed autologous hematopoietic stem cell transplantation for multiple myeloma: high CR and VGPR rates do not translate into improved survival.

Journal: Bone marrow transplantation

Published: March 03, 2018

An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes.

An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes.

Journal: American journal of hematology

Published: March 15, 2017

A review of supportive care and recommended preventive approaches for patients with chronic lymphocytic leukemia.

A review of supportive care and recommended preventive approaches for patients with chronic lymphocytic leukemia.

Journal: Expert review of hematology

Published: December 15, 2015

Clinical regression of squamous cell carcinoma and keratoacanthomas in a patient treated with a hypomethylating agent.

Clinical regression of squamous cell carcinoma and keratoacanthomas in a patient treated with a hypomethylating agent.

Journal: International journal of dermatology

Published: September 25, 2012

Splenomegaly in myelofibrosis--new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors.

Splenomegaly in myelofibrosis--new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors.

Journal: Journal of hematology & oncology

Published: May 14, 2012

Showing 1-11 of 11

Last Updated: 09/26/2026